CRANBURY, N.J., June 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs." The claims in the issued patent cover a series of small molecule mimics for naturally occurring amino acids which can be used as building blocks in drug development. A small molecule mimic claimed in the issued patent is used in making PL-3994, Palatin's lead peptide mimetic natriuretic peptide receptor A agonist, which is in development for treatment of acute exacerbations of asthma, heart failure and refractory or difficult-to-control hypertension.
"The small molecule mimetics we have developed should help in the commercialization of peptide-based drugs," said Carl Spana, Ph.D., Palatin's President and CEO. "Compounds such as our PL-3994 which use small molecule mimetics have extended half-lives, and are resistant to normal clearance mechanisms. This results in a drug candidate that is very potent and has a pharmacological effect much longer than is typically seen with peptides."
PL-3994 and the related family of compounds were discovered and developed by Palatin scientists and are solely owned by Palatin. In addition to this issued U.S. patent, Palatin has a U.S. patent on the PL-3994 composition of matter, and pending applications or issued patents in selected countries outside the United States.
About PL-3994PL-3994 is a natriuretic peptide receptor A (NPR-A) agonist compound in development for treatment of acute exacerbations of asthma, heart failure and refractory hypertension. PL-3994 activates NPR-A, a receptor known to play a role in cardiovascular homeostasis. PL-3994, one of a number of natriuretic peptide receptor agonist compounds Palatin has developed, is a synthetic molecule incorporating a novel and proprietary amino acid mimetic structure. It has an extended half-life, with reduced affinity for the endogenous natriuretic peptide clearance receptor and significantly increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV